Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
711actual
Sites
234
Countries
Australia, Austria, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-13 | actual | When the study began enrolling |
| Primary completion | 2025-07-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-04 | actual | The whole study's end, after follow-up |
| First posted | 2020-08-27 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-02 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced or Metastatic Unresectable Urothelial Cancer
Interventions
- Drug: Sacituzumab Govitecan-hziy — also filed as IMMU-132, Trodelvy™, GS-0132
- Drug: Paclitaxel — also filed as Taxol®
- Drug: Docetaxel — also filed as Taxotere®
- Drug: Vinflunine — also filed as Javlor ®
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 42 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-08-30 · 2.0 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-04-06 · 1.2 MB · SAP_001.pdf
Publications
- PMID 39934055 — cited as background
- PMID 41277126 — linked by the registry
- PMID 39472646 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed